NO995776L - Fremgangsmåte for behandling av thrombosesykdommer - Google Patents

Fremgangsmåte for behandling av thrombosesykdommer

Info

Publication number
NO995776L
NO995776L NO995776A NO995776A NO995776L NO 995776 L NO995776 L NO 995776L NO 995776 A NO995776 A NO 995776A NO 995776 A NO995776 A NO 995776A NO 995776 L NO995776 L NO 995776L
Authority
NO
Norway
Prior art keywords
treatment
combination therapy
result
limited
thrombosis
Prior art date
Application number
NO995776A
Other languages
English (en)
Norwegian (no)
Other versions
NO995776D0 (no
Inventor
Brian William Grinnell
Joseph Anthony Jakubowski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO995776D0 publication Critical patent/NO995776D0/no
Publication of NO995776L publication Critical patent/NO995776L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • External Artificial Organs (AREA)
NO995776A 1997-06-05 1999-11-25 Fremgangsmåte for behandling av thrombosesykdommer NO995776L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4862897P 1997-06-05 1997-06-05
PCT/US1998/011071 WO1998055142A1 (en) 1997-06-05 1998-06-01 Methods for treating thrombotic disorders

Publications (2)

Publication Number Publication Date
NO995776D0 NO995776D0 (no) 1999-11-25
NO995776L true NO995776L (no) 2000-01-26

Family

ID=21955575

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995776A NO995776L (no) 1997-06-05 1999-11-25 Fremgangsmåte for behandling av thrombosesykdommer

Country Status (23)

Country Link
US (1) US6071514A (de)
EP (1) EP0882453B1 (de)
JP (1) JP2002502421A (de)
KR (1) KR20010013413A (de)
CN (2) CN1265598A (de)
AT (1) ATE286404T1 (de)
AU (1) AU741983B2 (de)
BR (1) BR9809932A (de)
CA (1) CA2293429A1 (de)
DE (1) DE69828462T2 (de)
DK (1) DK0882453T3 (de)
EA (1) EA199901112A1 (de)
ES (1) ES2235291T3 (de)
HU (1) HUP0003964A2 (de)
ID (1) ID23908A (de)
NO (1) NO995776L (de)
PL (1) PL337223A1 (de)
PT (1) PT882453E (de)
SI (1) SI0882453T1 (de)
TR (1) TR199903020T2 (de)
TW (1) TWI228042B (de)
WO (1) WO1998055142A1 (de)
ZA (1) ZA984698B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062828A1 (en) * 1996-04-30 2000-10-26 Medtronic, Inc. Autologous fibrin sealant and method for making the same
DE19781869T1 (de) * 1996-04-30 2000-03-16 Medtronic Inc Verfahren zur Herstellung eines autologen Fibrin-Blutstillungsmittels
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6953568B1 (en) * 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
EP1093814A1 (de) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Verwendung von Dipyridamole oder Mopidamol zur Herstellung eines Medikaments für die Behandlung und Vorbeugung von fibrinabhängigen Mikrozirkulationstörungen
EP1255556B1 (de) * 2000-02-04 2011-04-06 The Scripps Research Institute Neuroprotektive, antithrombotische und anti-entzündliche anwendungen von aktiviertem protein c
US7812132B2 (en) * 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030056244A1 (en) * 2000-05-02 2003-03-20 Ning Huang Feed additive compositions and methods
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US8906894B1 (en) 2000-07-27 2014-12-09 Thomas N. Thomas Methods for preventing and treating thrombotic disorders
WO2002030889A2 (en) * 2000-10-13 2002-04-18 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US6942880B1 (en) * 2001-04-09 2005-09-13 Medtronic, Inc. Autologous platelet gel having beneficial geometric shapes and methods of making the same
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
US6838432B2 (en) * 2001-09-19 2005-01-04 Oklahoma Medical Research Foundation Treatment of sepsis with TAFI
PT1448205E (pt) * 2001-10-05 2011-07-05 Zalicus Inc Combinações para o tratamento de distúrbios munoinflamatórios
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
EP1773371A4 (de) * 2004-07-23 2009-12-30 Univ Rochester Aktiviertes protein c hemmt unerwünschte effekte von plasminogenaktivator im gehirn
SI2007362T1 (sl) * 2006-04-04 2018-12-31 Kg Acquisition Llc Peroralne odmerne oblike, ki vključujejo antitrombocitno sredstvo in inhibitor kisline
US9096839B2 (en) * 2006-04-26 2015-08-04 Arteriocyte Medical Systems, Inc. Compositions and methods of preparation thereof
US20080003213A1 (en) * 2006-05-22 2008-01-03 Jan Lessem Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels
CA2685331C (en) 2007-04-27 2016-07-05 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
EP2203174A4 (de) * 2007-09-19 2010-09-29 Combinatorx Inc Therapeutische schemata zur behandlung von immunentzündlichen erkrankungen
EP2231129A4 (de) * 2007-12-17 2013-01-30 Zalicus Inc Therapeutische schemata zur behandlung von immunentzündlichen erkrankungen
DE102007063234A1 (de) * 2007-12-31 2009-07-02 Nowak, Attila, Dipl.-Ing. Schnellere Speicherorganisation
US20100280594A1 (en) * 2009-05-01 2010-11-04 Medi-Solve, Llc Antithrombotic Neurovascular Device Containing a Glycoprotein IIB/IIIA Receptor Inhibitor for The Treatment of Brain Aneurysms and/or Acute Ischemic Stroke, and Methods Related Thereto
KR20190071006A (ko) 2009-05-13 2019-06-21 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
WO1993009807A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
JPH05271098A (ja) * 1992-03-26 1993-10-19 Teijin Ltd 活性化プロテインｃを有効成分とする抗血小板剤
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicyclic compounds and pharmaceutical compositions containing them
WO1997020043A1 (en) * 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals

Also Published As

Publication number Publication date
PT882453E (pt) 2005-04-29
CA2293429A1 (en) 1998-12-10
BR9809932A (pt) 2000-08-01
SI0882453T1 (en) 2005-06-30
EA199901112A1 (ru) 2000-06-26
DE69828462T2 (de) 2005-12-15
KR20010013413A (ko) 2001-02-26
CN1265598A (zh) 2000-09-06
TWI228042B (en) 2005-02-21
JP2002502421A (ja) 2002-01-22
DE69828462D1 (de) 2005-02-10
US6071514A (en) 2000-06-06
WO1998055142A1 (en) 1998-12-10
ZA984698B (en) 2000-02-01
ID23908A (id) 2000-05-25
AU7710098A (en) 1998-12-21
CN1347734A (zh) 2002-05-08
NO995776D0 (no) 1999-11-25
EP0882453A2 (de) 1998-12-09
PL337223A1 (en) 2000-08-14
DK0882453T3 (da) 2005-05-09
HUP0003964A2 (en) 2001-03-28
EP0882453B1 (de) 2005-01-05
ATE286404T1 (de) 2005-01-15
ES2235291T3 (es) 2005-07-01
EP0882453A3 (de) 2001-04-04
AU741983B2 (en) 2001-12-13
TR199903020T2 (xx) 2000-08-21

Similar Documents

Publication Publication Date Title
NO995776L (no) Fremgangsmåte for behandling av thrombosesykdommer
IL143870A0 (en) Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
BR0107230A (pt) Método de tratamento superficial de implantes ou próteses feitos em titânio ou outros materiais
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
FI952302L (fi) Pyran-2-onit ja 5,6-dihydropyranonit, jotka ovat käyttökelpoisia HIV:n ja muiden retrovirusten hoidossa
BR0212039B1 (pt) dispositivo terapêutico a laser de nìvel baixo.
NO993396L (no) Kinolin- og kinolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi
IL109802A0 (en) Pharmaceutical agents for treatment of emesis
NO20013064L (no) Kombinasjonsterapi med bestraling og en cox-2-inhibitor ved behandling av neoplasia
ATE235495T1 (de) 8-arylalkyl- und 8-arylheteroalkyl-5, 11-dihydro- 6h-dipyrido-(3,2-b:2', 3'-e)(1,4)diazepine und ihre verwendung zur vorbeugung oder behandlung von hiv-infektion
DE69841041D1 (de) Stent beschichtet mit dna
ATE361075T1 (de) Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
DE60037032D1 (de) Anwendung von pdt zur inhibierung von hyperplasie der intima
ID23189A (id) Komposisi pengelentang
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
DK664188A (da) Butylhydroxyanisoler til behandling af retrovirale sygdomme
CA2297984A1 (en) Ratite extracts as therapeutic agents
DK0836853T3 (da) Anvendelse af bradykinin-antagonister til fremstilling af lægemidler til behandling og forebyggelse af Alzheimers sygdom
NO984198L (no) FremgangsmÕte for behandling av aggresjon
ATE314073T1 (de) Kombination von aktiva mit alfuzosin und apomorphin
ITVR920053V0 (it) Vaporizzatore comprendente organi per il dosaggio, la diffusione e la vaporizzazione dell'acqua applicabile preferibilmente su forni modula-ri o similari
MX174250B (es) Composicion con actividad antiagregante de plaqueta util en terapias
ATE94759T1 (de) Verwendung von dextransulfat, gegebenenfalls in kombination mit anti-androgenen mitteln zur behandlung des humanen protatakarzinoms.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application